NTAP for Medical Devices: Temporary Hospital Add-Ons, Not a Device Price

A medical device NTAP payment is a temporary Medicare add-on to a hospital’s inpatient payment when the usual bundled rate inadequately covers a qualifying new technology. The hospital receives the add-on. The manufacturer sells the device. For someone in reimbursement or market access, the question that matters is what happened between the company’s payment pitch and the hospital’s claim: which device, which use, which code and which payment rule.

The Device Is Usually Inside the Hospital Payment

Medicare generally includes an implanted device’s cost in payment for the procedure or hospital stay. Under the inpatient prospective payment system, the hospital case falls into a Medicare severity diagnosis-related group, commonly called an MS-DRG. The group payment absorbs the device cost along with the other costs of care.

New technology add-on payments address a specific problem with that arrangement. A new technology can reach hospitals before the ordinary rate adequately reflects its cost. The add-on supplies temporary additional payment while the cost becomes reflected in the bundled system. That matters when the hospital deciding whether to buy a device also bears the cost of using it.

The device’s purchase price, the hospital’s charge and Medicare’s payment answer different questions. Purchasing knows what the product costs the hospital. A charge identifies what the hospital bills. Medicare applies its payment method to the case. A device can appear in the hospital’s billing information while its cost remains inside the bundle.

Food and Drug Administration authorization, Medicare coverage, coding and payment each have their own job. Authorization permits marketing. Coverage determines whether Medicare pays for the use. Coding describes the service or technology. Payment determines the amount and the unit being paid. A reimbursement presentation that slides between those decisions can leave the hospital expecting money that the actual claim must still qualify to receive.

What Qualifies a Device for NTAP?

The traditional NTAP pathway requires newness, a cost showing and substantial clinical improvement. The program overview from the Centers for Medicare & Medicaid Services describes those separate tests. The manufacturer has to address the technology’s place in Medicare’s payment system as well as its place in clinical practice.

Newness has a short life. The usual window is two to three years, and the agency stops treating the technology as new once it has recalibrated the MS-DRGs to reflect the cost. It also compares the technology with existing products: how it works, the payment group and the disease and patient population it treats. A fresh marketing authorization does not restart the clock for a substantially similar technology.

The cost test examines whether the charges for cases involving the technology exceed the applicable threshold. That is a hospital-case comparison. The device’s price enters a larger calculation about whether the ordinary group payment is adequate.

Substantial clinical improvement asks what the technology adds for Medicare beneficiaries compared with available care. The Centers for Medicare & Medicaid Services considers advances such as treating patients who lack a suitable existing option, finding a condition earlier in a way that changes patient management, or improving clinical outcomes. Evidence about fewer complications, fewer later interventions or faster recovery can carry that comparison.

The agency expressly distinguishes its clinical-improvement inquiry from the Food and Drug Administration’s marketing decision. For a healthcare reimbursement team, the clinical comparison presented to CMS and the benefit described to hospital buyers belong beside each other. They show what the company said the technology would do, for whom, and against which existing treatment.

How Are NTAP Payments Calculated?

For an eligible device, Medicare pays the smaller of two amounts, subject to the technology’s published maximum:

• 65 percent of the technology’s cost.
• 65 percent of the amount by which the hospital case’s cost exceeds the standard DRG payment.

The Centers for Medicare & Medicaid Services converts hospital charges to costs using cost-to-charge ratios. If the case’s costs do not exceed the full DRG payment, Medicare pays no add-on. A published maximum describes the ceiling, not a payment the hospital receives for every use.

This is why a reimbursement model that multiplies the maximum by every anticipated procedure needs closer examination. It assumes each case reaches the cap. The hospital’s actual payment depends on the qualifying case and its costs. Even when an add-on pays, the formula covers only part of the technology cost or the excess case cost.

Breakthrough Devices and the Change After FY 2027

The Breakthrough Device alternative pathway removed the separate substantial-clinical-improvement test for qualifying devices. Beginning with discharges on October 1, 2020, it required the Food and Drug Administration designation, marketing authorization for the designated indication, the newness window and the cost criterion. The clinical-improvement showing was waived.

The FY 2027 inpatient final rule took effect on October 1, 2026. The Centers for Medicare & Medicaid Services approved 19 new technologies for that fiscal year: 16 Breakthrough Devices through the alternative pathway and three drugs or biologics through the traditional pathway. The program offered extra public money without requiring those device makers to show CMS that patients would fare better.

That distinction matters to anyone reading a claim that Medicare recognized a device’s superior clinical benefit. The approval route tells the hospital what the agency actually evaluated. A decision to provide an add-on under the alternative pathway carries a different clinical-evidence requirement from a traditional-pathway approval.

What Changes for FY 2028 Applications?

The final rule ends the alternative pathway beginning with FY 2028 applications, subject to a limited transition. Applicants outside that exception must demonstrate all the traditional criteria, including substantial clinical improvement and that the technology is not substantially similar to an existing technology.

For devices, the transition preserves alternative-pathway applications for FY 2028 and FY 2029 when the device received Breakthrough designation by September 30, 2026, and receives marketing authorization for the designated indication by May 1, 2028. For each application, marketing authorization remains due by May 1 before the payment fiscal year.

Devices already approved under the alternative pathway, including the FY 2027 approvals, remain eligible for continued add-ons subject to the continuing-payment requirements. A sales forecast spanning the transition needs to identify the particular device’s approval and payment period, because a general reference to Breakthrough status leaves out the decision that determines the add-on.

What Is Behind the Manufacturer’s Number?

Manufacturer cost and utilization information can change an NTAP maximum. The AGENT paclitaxel-coated balloon catheter shows how: the applicant asked CMS to account for more than one device used in a hospital case.

In the final rule, the agency recounted the applicant’s analysis of inpatient claims showing an average of 1.19 devices per case. The applicant also cited published clinical studies and international registries. The Centers for Medicare & Medicaid Services accepted updated cost information and set the FY 2027 maximum at $4,776. The change concerned how many devices went into a case, a different question from the price of one catheter.

For someone who worked on that kind of submission, the important comparison runs from the utilization analysis to the reimbursement model and the sales presentation. Does the presentation preserve the assumptions behind the maximum? Does it describe a per-case cap as though it were the amount paid for each device? We examine the underlying documents with the insider, including what the hospital understood when it adopted the technology.

Estimated Spending and Actual Payments

The Centers for Medicare & Medicaid Services estimated approximately $418 million in FY 2027 payments for the newly approved alternative-pathway technologies, based on preliminary information from applicants. Its broader program estimate, including continuing technologies and new traditional-pathway approvals, was $1,739,715,745.

A hospital-facing model may begin with an approved maximum and a projected volume. The claims and payment records show which uses qualified and what Medicare paid. The evidence worth bringing to us is the connection between the representation, the hospital’s decision and the submitted claims.

NTAP Versus Outpatient Device Pass-Through

NTAP applies to qualifying inpatient hospital cases. Outpatient device pass-through is a separate temporary payment attached to a device category. The distinction begins with the setting in which the patient receives care.

Pass-through categories run for at least two years and no more than three. Payment uses the hospital’s device charges adjusted to cost, then subtracts the device amount already included in the procedure payment. That subtraction is the device offset. Category eligibility also means qualifying products from competing manufacturers can fit the same category.

The manufacturer-input issue appears here too. In the CY 2026 outpatient rule, the agency explained that early estimates use device cost and projected utilization from manufacturers’ applications. As outpatient claims data become available, it updates the estimates. For a device company selling into both settings, the hospital’s reimbursement story must follow the setting, the category or technology approval, and the relevant payment period.

The Code Connects the Device to the Case

The hospital claim must identify the qualifying technology and use. For specified FY 2027 technologies, the final rule points to code tables that identify the relevant indication or exclude cases involving a different technology. Coding is where the approved use meets the patient’s actual case.

Manufacturer coding advice belongs beside the clinical documentation and the hospital’s claim. The advice shows what the company told the hospital to report. The clinical documentation shows what happened. The claim shows which representation reached Medicare. Those comparisons are especially useful when reimbursement staff know that a sales message left out a restriction appearing in the approval or the underlying evidence.

When Reimbursement Advice Reaches a False Claim

Medical device reimbursement fraud can begin with a manufacturer’s instruction and end with a provider’s bill. TranS1, later called Baxano Surgical, agreed to a $6 million settlement in July 2013 over allegations that its promotion and coding conduct caused false reimbursement claims for minimally invasive spine procedures.

A separate whistleblower complaint concerning Semler’s QuantaFlo device alleged that the company told a provider to use specified billing codes. It then alleged:

The alleged refusal matters because the advice could reach the bill without appearing in the written reimbursement materials. The insider may know what the company said, who received it and how it affected billing.

A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, published in the Journal of Forensic and Investigative Accounting in 2020, examines how false statements connect to payment requests. Its analysis asks whether a false statement is what got the bill paid. That is the connection we pursue with a device insider: the company’s representation, the decision it influenced and the government bill it produced.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. If you know how a health care reimbursement pitch became a false claim, the details inside the business can be the starting point for that case.

When You Know How the Payment Was Sold

If you work in device reimbursement, market access or hospital billing and know where the payment pitch departed from the facts, talk to our whistleblower experts about the claims it produced. We work with you to connect the application, the sales message and the hospital bill, and build a medical device whistleblower case around what happened. We bring in medical device fraud whistleblower lawyers who understand hospital payment and stay beside you through the case.